newsfilter
← Latest News
GlobeNewswire·

Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

– Data reconfirm previously highlighted safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) – GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technolo